Premium
Retracted : Physcion Synergistically Enhances the Cytotoxicity of Sorafenib in Hepatocellular Carcinoma
Author(s) -
Pan Xiaoping,
Wang Chen,
Zhang Ti
Publication year - 2019
Publication title -
the anatomical record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.678
H-Index - 62
eISSN - 1932-8494
pISSN - 1932-8486
DOI - 10.1002/ar.24179
Subject(s) - sorafenib , hepatocellular carcinoma , in vivo , cancer research , apoptosis , cytotoxicity , malignancy , in vitro , pharmacology , medicine , oncology , chemistry , biology , biochemistry , microbiology and biotechnology
Hepatocellular carcinoma (HCC) is a common human malignancy. Physcion is a naturally occurring anthraquinone derivative found in plant and marine sources. Our previous studies have indicated that physcion could suppress tumor growth and induce apoptosis in HCC. This study was aimed to investigate the effect of a combination of physcion and sorafenib on HCC. Our findings indicated that physcion could significantly augment the antiproliferative and proapoptotic activities of sorafenib in vitro and in vivo . Mechanistically, the synergistic effect correlates with physcion‐induced suppression of Notch3/AKT signaling. This preclinical evidence highlights the potential application of physcion in the treatment of HCC. Anat Rec, 302:2171–2177, 2019. © 2019 American Association for Anatomy